The first-in-class erythroid maturation agent luspatercept shows significant clinical activity in patients with myelofibrosis-associated anemia, according to the interim results of a phase 2 study.
The NCCN has introduced the nation’s first-ever guidelines for systemic mastocytosis, a rare, complex and sometimes aggressive hematologic disease.
A multicenter team studied the safety of immunotherapy atezolizumab in patients with myelodysplastic syndrome who had either failed or never received conventional HMA therapy.
Retreatment with ruxolitinib can successfully reduce spleen size and other myelofibrosis symptoms when it didn’t the first or even second time, shows new study.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Cleveland Clinic hematologist Aaron Gerds, MD, shares how Twitter is helping him save time and connect with patients. Read his perspective article in ASH Clinical News.
Many assumed the story of PAC for patients with myelofibrosis had ended when the FDA placed it on hold in 2016, but the release of the hold in early 2017, the publishing of PERSIST-2’s phase 3 results, and the enrolling PAC203 trial show that the story of this JAK inhibitor is far from over.
Aaron Gerds, MD, examines whether social media use in medicine is dumbing down the discourse or accelerating and liberating peer review.
A review of trials examining several new approaches, including agents that inhibit various points in the Janus kinase and other pathways that underlie the condition, as well as potential concomitant agents that can help minimize anemia and/or thrombocytopenia to enable more effective dosing of primary treatments.
Cleveland Clinic Taussig Cancer Institute’s Aaron Gerds, MD, MS, helped draft the guidelines as a member of both the panel and the Discussion Writing Committee. He explains here why the National Comprehensive Care Network guidelines were developed and how to use them.
The oral kinase inhibitor pacritinib (PAC) yielded greater spleen volume reduction than best available therapy — including ruxolitinib — for myelofibrosis patients. If PAC passes the safety test, the impact could be huge.